Clinical TopicsOncologyUncategorizedWeb Exclusives

FDA expands use of Xalkori

Share

On March 11, the Food and Drug Administration (FDA) approved Xalkori (crizotinib) to treat people with metastatic non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC. Read more

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Test Your Knowledge

Which of the following statements accurately describes hypertrophic cardiomyopathy (HCM)?

Recent Posts